$BLU - From a technical standpoint, a small rebound is imminent imo. The further we go down into the oversold territory, the higher it will be. Also, the MACD is beginning to curl upward. Outside of that, going long here is a bad idea. They don’t have a great history with trials, they will need more cash flow to drive phase 2b of their trial and future phases, and their marketable populous just shrunk with the phase 2 results which means profitability is year and years away. They are hanging on by a string here.